News Release

ebook Describes the Role of the Innate Immunity Proteome As a Central Modulator of Disease from Pandemic Infections to Cancer

MONMOUTH JUNCTION, NJ, May 7, 2020 -- Biotech Support Group reports on an ebook describing how the innate immune response can be categorized and reported by new strategies for proteomic analysis.

The BSG ebook is entitled:

“Categorization of Blood Based Biomarkers – Unleashing the Power of Proteomics To Better Understand the Innate Immune Response to Infectious and Non-infectious Inflammatory Stimuli”, April 17, 2020

This ebook describes the focus of BSG; how to address quantitative differences between proteins in blood samples representing a challenge or disease state, vs. samples representing a normal or control state. For this purpose, BSG’s products and methods can help proteomic investigators explore all blood compartments. Furthermore, as unresolved inflammatory stimuli can lead to chronic disease and pre-dispose individuals to severe acute responses, the ebook describes new categorization strategies for selection of innate immunity biomarker proteins. Finally, the ebook describes how past proteomic analysis based on antigen recognition can lead to egregiously misleading information on the status of protease regulation in the general blood circulation.

“Proteomics started with coverage annotation and Venn diagrams but now the field demands robust quantitation. This is so we can discover and validate new biomarkers which are desperately needed to improve patient outcomes, both in deciding the best standard of care with current therapies, but also to help develop personalized treatments in the future. For this, proteomics provides an essential technology platform. By adopting BSG’s products to enrich blood-derived protein biomarkers of low-abundance to mid-abundance, we can improve linearity between targeted peptide LC-MS ion signals and protein abundances.This can be done with consumable sample prep products that are not based on immuno-affinity, creating simple and quantitatively robust workflows. As a result, the convergence of proteomic technologies has made the task immediately available to understand the role of the innate immunity proteome within the pathogenesis of many diseases from our current COVID-19 pandemic, to cancer and autoimmune disease.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on all of our consumable sample prep products, visit:

https://www.biotechsupportgroup.com/Products-a-z_a/258.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com